Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study


Fung S., Kwan P., Fabri M., Horban A., Pelemis M., Hann H., ...More

JOURNAL OF HEPATOLOGY, vol.66, no.1, pp.11-18, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 66 Issue: 1
  • Publication Date: 2017
  • Doi Number: 10.1016/j.jhep.2016.08.008
  • Journal Name: JOURNAL OF HEPATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.11-18
  • Keywords: Tenofovir disoproxil fumarate, Emtricitabine, Lamivudine resistant, Viral suppression, Bone mineral density, Renal function, LONG-TERM EFFICACY, VIRUS INFECTION, COMBINATION THERAPY, ADEFOVIR, ENTECAVIR, SAFETY, MONOTHERAPY, CIRRHOSIS, LEVEL, RISK
  • Bursa Uludag University Affiliated: Yes

Abstract

Background & Aims: Long-term treatment with tenofovir disoproxil fumarate (TDF) alone, or in combination with emtricitabine (FTC) is associated with sustained viral suppression in patients with lamivudine resistant (LAM-R) chronic hepatitis B (CHB).